Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
764.440.02%
QQQ
715.040.02%
BTC/USD
77572.521.0061%
DIA
525.910.02%
GLD
398.290.12%
TLT
80.930.07%

Akari Therapeutics PLC (AKTX) Stock Price, Quote, News & History

AKTXNASDAQ
Trade with Public
Trade with Public
$11.30
0.423.86%
At close: Sep 11, 5:00 PM EST
$12.62
1.3211.68%
After Hours: Sep 11, 6:45 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Akari Therapeutics (AKTX) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$10.51
Close
$11.30
Volume / Avg.
135.28K / 76.18K
Day Range
$10.51 - $11.50
52 Wk Range
3.02 - 49.60
Market Cap
$24.57M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
69
Short Interest
2.7%
Days to Cover
1

Recent Akari Therapeutics PLC News

Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy

Akari Therapeutics reports positive preclinical data for AKTX-101 in urothelial cancer, showing efficacy in models resistant to current ADCs.
Vandana Singh

Why Amazon Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

Amazon reported strong Q2 results, beating revenue and earnings estimates. Shares jumped 11.9% in pre-market trading while other stocks also saw gains/losses.
Avi Kapoor

VNET Group, Akari Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

US stock futures up, VNET Group shares down 3.8% after reporting Q1 loss of $(1.20) per share on $390.133 million sales. Other stocks also fall.
Avi Kapoor

Why Akari Therapeutics Stock Is Falling On Tuesday?

Discover why Akari Therapeutics PLC (NASDAQ: AKTX) stock is falling on Tuesday after last week's massive 255% rally on positive preclinical cancer data.
Kaustubh Bagalkote

Why JOYY Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, CODX +22.7%, MDAI +22%. Losers: AKTX -25.2%, RYOJ -18.6%, DEVS -18.6%, AKAN -17%, ADTX -16.3%, LFS -15.6%
Avi Kapoor

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-10.76M
Investing Cash Flow (TTM)
-
Financing Cash Flow (TTM)
15.75M
Free Cash Flow (TTM)
-10.76M
Capital Expenditure (TTM)
-
Net Change in Cash (TTM)
4.99M

Analyst Trends and Forecast

1
Apr
1
Jul
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$15.00M
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
-
PB Ratio (TTM)
1.15
Earnings Yield % (TTM)
0.00%
Earnings Yield % (FWD)
-7.26%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$9.55

Company Debt

Total Debt
$693.00K
LT Debt
-
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-
Total Cash
$7.69M
Debt to Equity
0.04
Issuance of Debt (TTM)
-
Repayment of Debt (TTM)
-$662.00K

Key Statistics

Open
$10.51
Close
$11.30
Volume / Avg.
135.28K / 76.18K
Day Range
$10.51 - $11.50
52 Wk Range
3.02 - 49.60
Market Cap
$24.57M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
69
Short Interest
2.7%
Days to Cover
1

About

Sector
Health Care
Industry
Biotechnology
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the sp...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Akari Therapeutics (AKTX) stock?

A

You can purchase shares of Akari Therapeutics (NASDAQ:AKTX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Akari Therapeutics (AKTX) competitors?

Q

What is the forecast, or price target, for Akari Therapeutics (AKTX) stock?

A

Akari Therapeutics has a consensus price target of $32.33.

Q

What is the current price for Akari Therapeutics (AKTX)?

A

The stock price for Akari Therapeutics (NASDAQ: AKTX) is $12.62 last updated September 11, 2026 at 6:45 PM EDT.

Q

Does Akari Therapeutics (AKTX) pay a dividend?

A

There are no upcoming dividends for Akari Therapeutics.

Q

When is Akari Therapeutics (NASDAQ:AKTX) reporting earnings?

A

Akari Therapeutics does not have any upcoming earnings scheduled.

Q

Is Akari Therapeutics (AKTX) going to split?

A

There is no upcoming split for Akari Therapeutics.

Q

What sector and industry does Akari Therapeutics (AKTX) operate in?

A

Akari Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved